Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Wakefield AJ, More LJ, Difford J, Mclaughlin JE
It has demonstrated a strong safety profile and is currently used for non-therapeutic experimental applications only
It's not a shortcut
For this reason, Gao and his group developed a series of nanoplatforms on the basis of acidic cleavable ligand modification
The results of the excretion experiment showed that the main excretory pathways of BPC157 involve the liver and kidney, which was also consistent with the excretion characteristics of peptide drugs (Czock et al., 2012
FDAs 2023 Category 2 placement cited immunogenicity risk for certain routes of administration, peptide-related impurities, complexities in active pharmaceutical ingredient (API) characterization, and limited safety information for the proposed routes
